Search

Your search keyword '"Mollapour, Mehdi"' showing total 500 results

Search Constraints

Start Over You searched for: Author "Mollapour, Mehdi" Remove constraint Author: "Mollapour, Mehdi"
500 results on '"Mollapour, Mehdi"'

Search Results

2. Second international symposium on the chaperone code, 2023

3. Editorial : A new chapter for Cell Stress and Chaperones

4. Catalytic inhibitor of Protein Phosphatase 5 activates the extrinsic apoptotic pathway by disrupting complex II in kidney cancer.

5. Second Virtual International Symposium on Cellular and Organismal Stress Responses, September 8–9, 2022

19. The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect

22. Activation of autophagy depends on Atg1/Ulk1-mediated phosphorylation and inhibition of the Hsp90 chaperone machinery

31. Fanconi anemia complementation group C (FANCC) gene association with hereditary and sporadic renal tumors (RT).

32. Comprehensive genomic profiling of histologic subtypes of urethral carcinomas

33. Molecular genetic analysis of preservative resistance in Zygosaccharomyces bailii

34. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma

39. Second Virtual International Symposium on Cellular and Organismal Stress Responses, September 8–9, 2022 [Meeting Review]

41. Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors

43. Supplementary Figure 4 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

44. Supplementary Figure 1 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

45. Supplementary Figure Legend from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

46. Supplementary Table 1 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

47. Supplementary Figure 3 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

48. Data from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

49. Supplementary Figure 5 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

50. Supplementary Table 2 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Catalog

Books, media, physical & digital resources